Each year, the EULAR congress continues to grow larger and larger. Ensuring an exciting and fulfilling programme is an enormous undertaking…

Since the 1990s, outcomes for patients with RA have steadily improved over time, with the treatment target for patients evolving from symptomatic relief…

Type I IFN have important roles in many paediatric and adult rheumatic diseases and are a new therapeutic target for which several anti-IFN treatments…

The aim of this symposium was to familiarise participants with the IL-23 pathway and the rationale for targeting this pathway in PsA…

The field of immunometabolism is a rapidly expanding area of research that centres around understanding the interrelationship between immunological and…

Immunogenicity constitutes an important concern since it is associated with lower clinical responses and more adverse events…

Osteoporosis is a systemic skeletal disease characterised by microarchitectural deterioration and high fragility of bone tissue, resulting in low bone…

Although aPL are reported in 1–5% of the general population,2 only a minority of these individuals will develop the clinical manifestations of APS. The incidence of APS…

Psoriatic arthritis (PsA) belongs to the group of diseases known as spondyloarthritis (SpA). The impact of PsA is not limited to just skin and joints…

Adalimumab is a recombinant fully human monoclonal antibody (IgG1 type) targeting soluble and transmembrane TNF. AbbVie’s bio-originator adalimumab…